XJPX
7096
Market cap47mUSD
Oct 09, Last price
746.00JPY
1D
-0.27%
1Q
-2.86%
IPO
-61.94%
Name
StemCell Institute
Chart & performance
P/E
48.18
P/S
2.67
EPS
15.48
Div yield, %
3.34%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
14.81%
Revenues
2.81b
+4.93%
Net income
156m
-59.59%
CFO
74m
-84.28%
Dividend
Sep 27, 202425 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
Key people
Takafumi Shimizu
President, Representative Director · since 2016
Kei Kayano
Executive Officer, Chief Financial Officer, Chief Director of Finance and Accounting in Administrative Unit · since 2025
Mamoru Ishii
Executive Officer · since 2022
Hideaki Sato
Executive Officer · since 2022
Katsuhiro Tani
Executive Officer, Senior Chief Director of Human Resource and General Affairs in Administration Unit · since 2025
Kakushi Tsuchiyama
Executive Officer · since 2022
Kimihide Ando
Independent Director · since 2020
Yumi Okubo
Independent Director · since 2023
Tomoo Yamada
Independent Director · since 2019
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||